FILTERED RESULTS
FILTERS
Ads Top
•
·
·
FILTERED RESULTS
U.S. CRUDE OIL FUTURES SETTLE AT $89.61/BBL, SURGING $5.76 OR 6.87%....
Submit your questions: What does AI really mean for your work?
TRUMP: THE IRANIAN LEADERSHIP HAS REDIRECTED HUNDREDS OF SHIPS TOWARDS THE U.S., PRIMARILY TO...
Tech Stocks Crashed — But Wall Street Says The Worst May Be Over
Bank of Canada names Gosselin, Vincent as deputy governors
Theriva Biologics stock surges on AACR cancer trial data
FAA orders investigation into Blue Origin flight mishap
Global Continuous Emission Monitoring Systems Market Size/Share Worth USD 9.67 Billion by 2035 at a 9.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)
DRAM ETF Surpasses $1B Assets Since Early April Launch
THE ISLAMIC COALITION PARTY BACKS IRANIAN PARLIAMENT SPEAKER QALIBAF, ACCORDING TO ILNA....
In HelloNation, Plumbing Expert Ken Settje Explains Causes of Low Water Pressure
Test Your ETF Knowledge In Our IQ Test
Building products sector faces margin squeeze as inflation headwinds mount - Wolfe
Stocks slip amid uncertainty over Iran peace talks following ship seizure by U.S.
Feds Start Processing $127 Billion in Tariff Refunds for Importers
BANK OF CANADA APPOINTS MARC-ANDRE GOSSELIN AND NICOLAS VINCENT AS NEW DEPUTY GOVERNORS, EFFECTIVE...
POET Technologies Inc.(POET) Stock: Rallies on AI Growth and $375M Funding
China's Private Sector Answer To Nuclear Fusion - NovaFusionX
In HelloNation, Electrical Expert James Lagomarsino Offers Guidance on Hiring an Electrical Contractor
Bank of Canada Adds Gosselin, Vincent to Full-Time Rate-Setting Council
Kuwait Declares Further Force Majeure on Oil Shipments
Heathrow can raise airline fees to pay for third runway bid, regulator says
Enhancing Customer Due Diligence with a Control Plane Approach
Coinbase Partners with Bybit for Stock Tokenization
Alphabet Remains a Strong Investment Choice for Investors
Google to Unveil New Inference AI Chips at Cloud Next Event
Investing in Dividend Aristocrats for Passive Income
Trade Desk Shares Rise 7% Amid Jefferies Concerns
CBRE Group Set to Release Q1 2026 Earnings Report
Crown Castle Anticipates Revenue Challenges Ahead of Q1 Earnings
Veralto Demonstrates Strong Fundamentals Amid Growth Concerns
UnitedHealth Anticipates $6 Billion Impact from Medicare Payment Overhaul
Iranian Foreign Minister Criticizes U.S. Actions in Diplomatic Talks with Russia
USA Rare Earth, Inc. (USAR) Stock: Surges as $2.8B Serra Verde Deal Signals Global Expansion
Spirit Floats Government Stake to Avoid Possible Liquidation
Junk-Rated LA Children’s Hospital to Borrow for Working Capital
U.S. STATE DEPARTMENT: WASHINGTON WILL NOT HOST A SECOND ROUND OF NEGOTIATIONS BETWEEN THE LEBANESE...
State Street Had A 'Blockbuster' Q1, Analyst Says
'Think Even Bigger': Michael Saylor Drops $2.54 Billion On Bitcoin, But What Do Prediction Markets Say?
BAIN CAPITAL IS THE SOLE BIDDER TO ACQUIRE VITABIOTICS, ACCORDING TO THE ECONOMIC TIMES....
Rising Material Costs Expected to Impact Holiday Prices
Companies with Strong Fundamentals Show Potential for High Returns
Three Stocks Highlighted for Strong Performance Potential
Iran's Foreign Minister Addresses Ceasefire Violations with Pakistan
Revolut Boss Says IPO Won’t Come Until at Least 2028
IRAN PLANS TO SEND NEGOTIATING TEAM TO PAKISTAN ON TUESDAY - WSJ....
THE ACQUISITION IS MEANT TO BOOST THE NOJIMA'S PRODUCT DEVELOPMENT CAPABILITIES- NIKKEI...
Aditxt, Inc. (ADTX) Stock: Ignite Platform Gains Spotlight in Cancer Study Breakthrough
US Crypto Adoption Recovers With Bitcoin Still in Top Spot
argenx Presents New Efficacy Data for VYVGART at Neurology Meeting
argenx SE has unveiled promising clinical data for its drug VYVGART at the 2026 American Academy of Neurology meeting. The data highlights VYVGART's efficacy in treating ocular myasthenia gravis, as well as broader generalized myasthenia gravis subtypes and chronic inflammatory demyelinating polyneuropathy.
This presentation marks a significant milestone as VYVGART becomes the first biologic treatment to demonstrate efficacy specifically in ocular myasthenia gravis. The findings support the company's plans for a supplemental filing with the U.S. Food and Drug Administration (FDA).
In addition to VYVGART, argenx reported advancements in its neuromuscular pipeline candidates, adimanebart and empasiprubart, indicating ongoing efforts to expand its therapeutic offerings in this area.
© 2026 KLEA News. All Rights Reserved. This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.
Source: KLEA News